This clinical trial is focused on studying treatments for newly diagnosed multiple myeloma, a type of cancer that affects plasma cells in the bone marrow. The study will explore different treatment combinations to see which is most effective. The treatments being tested include a combination of medications: Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone, as well as a new drug called Iberdomide (also known by its code name CC-220). These medications are used in various combinations to see how well they work in treating the disease.
The purpose of the study is to compare the effectiveness of these treatment combinations in patients who are candidates for a procedure called autologous stem cell transplant (ASCT). This procedure involves collecting a patient’s own stem cells, treating them with high doses of chemotherapy, and then returning the stem cells to the patient to help rebuild their bone marrow. The study will look at how well the treatments work in reducing the number of cancer cells in the bone marrow after 18 cycles of treatment, which includes different phases such as induction, consolidation, and continuous treatment.
Participants in the study will receive one of the treatment combinations and may also receive a placebo as part of the study design. The study will last for a maximum of 24 months, during which time the effectiveness of the treatments will be monitored. The goal is to find out which combination of treatments is most effective in helping patients achieve a state where no cancer cells are detected in their bone marrow, known as being MRD-negative (minimal residual disease-negative). This information will help doctors understand which treatments might be best for patients with newly diagnosed multiple myeloma.
Spain 
